Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
SoftOx Solutions AS is a biotechnology company specializing in developing infection control and wound care solutions. With a strong focus on addressing antimicrobial resistance, which is a growing concern in global health, SoftOx develops innovative products designed to combat bacterial infections without promoting resistance. Their key offerings span across the healthcare and veterinary sectors, including topical treatments and disinfectants that leverage proprietary non-alcoholic biocidal technology. The company's solutions are particularly significant in settings requiring high hygiene standards, such as hospitals, clinics, and animal husbandry. By contributing to the control of infections and reducing the dependence on traditional antibiotics, SoftOx Solutions AS plays a critical role in public health and safety. Based in Norway, SoftOx is actively involved in advancing research and development in biotechnology, aligning with global efforts to address crucial health challenges.
NOK 0.01
+NOK 0.00 (+0.00%)
EOD Jul 1, 2026
Free cash flow declined 248% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -NOK 19M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 0.00
Net Income (TTM)
-NOK 11M
▲ +74.8% YoY
Op. Margin
—
ROIC
-12.97%
▲ +15.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 19M
▼ -248.3% YoY
Op. Cash Flow (TTM)
-NOK 19M
▼ -167.1% YoY
Net Debt
-NOK 10M
Net Cash Position
Cash & Equiv.
NOK 20M
Continue Research
SoftOx Solutions AS (SOFTX.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, SoftOx Solutions AS scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
SoftOx Solutions AS scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -13.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SOFTX.XOSL's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.